Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

144.74
-2.7600-1.87%
Post-market: 144.910.1700+0.12%19:58 EDT
Volume:5.04M
Turnover:731.35M
Market Cap:179.58B
PE:-55.35
High:148.00
Open:147.65
Low:144.00
Close:147.50
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.99
T/O Rate:0.41%
Dividend:3.22
Dividend Rate:2.22%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.18
PE(LYR):21.35

Loading ...

Mubadala Investment Co Pjsc Reports Share Stake in Ford Motor, Phillips 66, Dissolves in Apple

Reuters
·
Aug 14

Your Prescription Drugs Shouldn't Cost More than Your Mortgage. Inside the Broken Math That Got US Here.

Dow Jones
·
Aug 14

Gilead Sciences (GILD) Gets a Hold from Barclays

TIPRANKS
·
Aug 14

Assembly Bio Releases Corporate Deck Highlighting Clinical-Stage Pipeline, Gilead-Partnered HSV Program

Reuters
·
Aug 14

Assembly Biosciences Q2 Net Loss Narrows as Revenue Rises

Reuters
·
Aug 14

Your Prescription Drugs Shouldn't Cost More than Your Mortgage. Inside the Broken Math That Got US Here.

Dow Jones
·
Aug 13

Moderna Inc. Stock Rises 5.1%, Outperforms Peers

Dow Jones
·
Aug 13

MacroGenics Rises on $10 Million Milestone Payment from Gilead

Reuters
·
Aug 12

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 12

MacroGenics Raih Pembayaran USD 10 Juta Usai Gilead Ambil Lisensi Program Bispesifik Praklinis

Reuters
·
Aug 12

MacroGenics - Remains Eligible to Receive up to Approximately $1.6 Bln in Additional Development

THOMSON REUTERS
·
Aug 12

Global Drugmakers Invest Billions to Boost US Presence

Reuters
·
Aug 11

Tango Falls After Wider-than-Expected Quarterly Loss

Reuters
·
Aug 11

Lakefront Biotherapeutics Boosts Immunology Push With Ouro Deal and Strong Cash Outlook

TIPRANKS
·
Aug 11

Lakefront Biotherapeutics H1 FY26 Net Sales Drop 87% to EUR 18.6 Million; Operating Loss Narrows 54% to EUR 107.2 Million

Reuters
·
Aug 11

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

MT Newswires Live
·
Aug 11

Global Drugmakers Invest Billions to Boost US Presence

Reuters
·
Aug 10

Erasca Appoints Charles Fuchs as President of R&D

Reuters
·
Aug 10

Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target

TIPRANKS
·
Aug 08

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 08